The goal of the study is to fulfill the mandate of "Carly's Law" and to provide patients with debilitating epileptic conditions with access to CBD as an add-on treatment. Other care including routine neurological care that is not related to participation in the CBD study will need to be provided by patients' primary/current treating neurologist.